A New Era in Targeting Multiple Pathways in Advanced Breast Cancer

IMPACT 2013 Industry Satellite Symposium

Friday, 3 May 2013
12.15−13.15

Silver Hall
SQUARE Brussels Meeting Centre
Museumstraat/8 rue du Musée
B-1000 Brussels
A New Era in Targeting Multiple Pathways in Advanced Breast Cancer

Friday, 3 May 2013
12.15−13.15

Silver Hall
SQUARE Brussels Meeting Centre
Museumstraat/8 rue du Musée
B-1000 Brussels

Chair
Sunil Verma, MD, MSEd, FRCPC
Toronto Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada

Faculty
Sara Hurvitz, MD
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States

Nicholas Turner, MA, MRCP, PhD
Institute of Cancer Research
London, United Kingdom

Agenda
Friday, 3 May 2013

Welcome and introduction
Sunil Verma, MD, MSEd, FRCPC

12.15
Inhibiting crosstalk between estrogen receptor (ER) and PI3K/AKT/mTOR pathways: What we know and what we would like to know
Nicholas Turner, MA, MRCP, PhD

12.30
Challenging patient scenarios from clinical practice in advanced breast cancer
Sunil Verma, MD, MSEd, FRCPC
Interactive Panel & Audience Discussion

13.00
What does the future hold for PI3K/AKT/mTOR inhibitors in breast cancer?
Sara Hurvitz, MD

13.15
Concluding remarks
Sunil Verma, MD, MSEd, FRCPC

Learning Objectives
After successful completion of this educational activity, participants should be able to:

- Describe the role of ER and PI3K/AKT/mTOR signaling in patients with advanced breast cancer
- Evaluate rationale and strategies to inhibit the PI3K/AKT/mTOR pathway
- Discuss optimal treatment options for patients with endocrine therapy–resistant advanced breast cancer
- Discuss the importance of early recognition and management of adverse events, in particular, with novel targeted agents
- Examine ongoing clinical trials with emerging PI3K/AKT/mTOR inhibitors and the unmet need for parallel translational research

This meeting is a prIME Oncology activity.

Support for this educational activity is provided by Novartis Oncology.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Register online at: www.prIMEoncology.org/Breast_Brussels